Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity

描述（由申请人提供）：朱莉B。Dumond，PharmD，BCPS，AAHIVE，在药学的Eshelman学校的药物治疗和实验治疗学的部门研究助理教授，是一个药剂师，在以患者为导向的研究方法的强大的培训和背景，并证明致力于应用这些方法来改善抗逆转录病毒（ARV）在艾滋病毒感染患者的使用。候选人的长期职业目标是成为一名独立资助的学术药物计量学家，在抗逆转录病毒药物的药代动力学/药效学建模方面拥有丰富而多样的经验。特别是，候选人将进行前瞻性群体药代动力学/药效学（PK/PD）数据收集，目的是量化影响药物反应和毒性的年龄相关因素。该职业发展奖培养的候选人的短期职业目标是1）获得高级PK/PD，生物统计学和计算方法的正式培训，2）获得群体PK/PD建模的实践经验，3）与领先的药物计量学家建立工作关系，4）开发R34/U 01或R 01应用的初步数据，（5）扩大她在负责任的研究培训方面的培训。拟议的研究计划，职业发展活动和导师团队都是唯一适合帮助申请人实现这些目标。研究计划是围绕中心假设建立的：1）改变ARV药代动力学有助于改变药效学（通过临床反应和毒性测量），2）实足年龄只能部分解释药代动力学的改变，以及随后的药效学。在本提案中，我们将针对两种常见的抗逆转录病毒治疗方案恩曲他滨/替诺福韦/依法韦仑（Atripla）和恩曲他滨/替诺福韦/阿扎那韦/利托那韦（Truvada、Reyataz和Norvir），开发两种特定目标的药代动力学和药代动力学/药效学模型。为了实现这些目标，我们将使用最佳样本设计模拟，前瞻性地收集药物浓度和药物反应数据，从艾滋病毒感染的成年人接受感兴趣的方案。受试者将从北卡罗来纳州大学（University of North Carolina）临床HIV队列中招募。为了支持候选人的职业发展，她将在药代动力学和药效学理论和建模，生物统计学，计算方法和研究伦理学领域进行高级课程和独立研究，并与实践建模培训相结合。导师团队，其中包括国际公认的，独立资助的研究人员在抗逆转录病毒临床药理学（卡舒巴），药物计量学（福雷斯特）和艾滋病毒临床护理和研究（科恩）的专业知识，将指导杜蒙德博士的研究，培训和专业发展。研究环境包括NIH资助的转化和临床科学研究所和艾滋病研究中心，以及纽约州立大学布法罗大学的药物科学系，将提供一个富有成效的、学院式的和协作的氛围，以实现上述研究和培训目标。 到2015年，美国超过50%的HIV感染人口将至少50岁，而对老年HIV感染患者的最佳临床护理知之甚少。这项研究和后续研究的目标是确定患者特异性因素，改变抗逆转录病毒反应和毒性。这可能会导致对老年艾滋病毒感染者的具体治疗建议。

DESCRIPTION (provided by applicant): Julie B. Dumond, PharmD, BCPS, AAHIVE, Research Assistant Professor in the Division of Pharmacotherapy and Experimental Therapeutics at the UNC Eshelman School of Pharmacy, is a pharmacist with strong training and background in patient-oriented research methodology, and a proven commitment to applying these methods to improving antiretroviral (ARV) use in HIV-infected patients. The candidate's long-term-career goal is to be an independently funded, academic pharmacometrician, with a rich and diverse experience in pharmacokinetic/pharmacodynamic modeling of antiretroviral drugs. In particular, the candidate will pursue prospective population pharmacokinetic/pharmacodynamic (PK/PD) data collection, with the goal of quantifying age-related factors that influence drug response and toxicity. The candidate's short-term career goals fostered by this career development award are 1) to obtain formal training in advanced PK/PD, biostatistics, and computational methods, 2) to gain hands-on experience in population PK/PD modeling, 3) to foster working relationships with leading pharmacometricians, 4) to develop the preliminary data for an R34/U01 or R01 application, and 5) to expand her training in the responsible training of research. The proposed research plan, career development activities, and mentorship team are all uniquely suited to assist the applicant in achieving these goals. The research plan is built around the central hypothesis that: 1) altered ARV pharmacokinetics contributes to altered pharmacodynamics as measured by clinical response and toxicity, and 2) chronological age may only partly explain alterations in pharmacokinetics, and subsequently, pharmacodynamics. In this proposal, we will develop a pharmacokinetic and a pharmacokinetic/pharmacodynamic model in two specific aims for two common ARV regimens, emtricitabine/tenofovir/efavirenz (Atripla) and emtricitabine/tenofovir/atazanavir/ritonavir (Truvada, Reyataz, and Norvir). To accomplish these aims, we will use optimal sample design simulation to prospectively collect drug concentration and drug response data from HIV-infected adults receiving the regimens of interest. Subjects will be recruited from the University of North Carolina (UNC) Clinical HIV Cohort. To support the candidate's career development, she will pursue advanced coursework and independent study in the areas of pharmacokinetic and pharmacodynamic theory and modeling, biostatistics, computational methods, and research ethics, in concert with hands-on modeling training. The mentorship team, which includes internationally-recognized, independently-funded investigators with expertise in ARV clinical pharmacology (Kashuba), pharmacometrics (Forrest), and HIV clinical care and research (Cohen), will guide Dr. Dumond's research, training, and professional development. The research environment including the NIH-funded Translational and Clinical Sciences Institute and Center for AIDS Research at UNC and the Department of Pharmaceutical Sciences at the University at Buffalo, State University of New York, will provide a productive, collegial, and collaborative atmosphere in which to pursue the above research and training goals. NARRATIVE By 2015, more than 50% of the HIV-infected population in the United States will be at least 50 years of age, and little is known about the optimal clinical care of aging HIV-infected patients. The goal of this and subsequent research is to identify patient-specific factors modifying antiretroviral response and toxicity. This could lead to specific treatment recommendations for older HIV-infected patients.